Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants
To assess vaccine immunogenicity in non-infected and previously infected individuals in a real-world scenario, SARS-CoV-2 antibody responses were determined during follow-up 2 (April 2021) of the population-based Tirschenreuth COVID-19 cohort study comprising 3378 inhabitants of the Tirschenreuth co...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/324 |
| _version_ | 1797476163090644992 |
|---|---|
| author | David Peterhoff Sebastian Einhauser Stephanie Beileke Hans-Helmut Niller Felix Günther Michael Schachtner Benedikt Asbach Philipp Steininger Matthias Tenbusch Antonia S. Peter Andre Gessner Ralph Burkhardt Iris M. Heid Ralf Wagner Klaus Überla |
| author_facet | David Peterhoff Sebastian Einhauser Stephanie Beileke Hans-Helmut Niller Felix Günther Michael Schachtner Benedikt Asbach Philipp Steininger Matthias Tenbusch Antonia S. Peter Andre Gessner Ralph Burkhardt Iris M. Heid Ralf Wagner Klaus Überla |
| author_sort | David Peterhoff |
| collection | DOAJ |
| description | To assess vaccine immunogenicity in non-infected and previously infected individuals in a real-world scenario, SARS-CoV-2 antibody responses were determined during follow-up 2 (April 2021) of the population-based Tirschenreuth COVID-19 cohort study comprising 3378 inhabitants of the Tirschenreuth county aged 14 years or older. Seronegative participants vaccinated once with Vaxzevria, Comirnaty, or Spikevax had median neutralizing antibody titers ranging from ID50 = 25 to 75. Individuals with two immunizations with Comirnaty or Spikevax had higher median ID50s (of 253 and 554, respectively). Regression analysis indicated that both increased age and increased time since vaccination independently decreased RBD binding and neutralizing antibody levels. Unvaccinated participants with detectable N-antibodies at baseline (June 2020) revealed a median ID50 of 72 at the April 2021 follow-up. Previously infected participants that received one dose of Vaxzevria or Comirnaty had median ID50 to 929 and 2502, respectively. Individuals with a second dose of Comirnaty given in a three-week interval after the first dose did not have higher median antibody levels than individuals with one dose. Prior infection also primed for high systemic IgA levels in response to one dose of Comirnaty that exceeded IgA levels observed after two doses of Comirnaty in previously uninfected participants. Neutralizing antibody levels targeting the spike protein of Beta and Delta variants were diminished compared to the wild type in vaccinated and infected participants. |
| first_indexed | 2024-03-09T20:54:03Z |
| format | Article |
| id | doaj.art-f3d9ef5fbe344190848271f6388c70c0 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:54:03Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f3d9ef5fbe344190848271f6388c70c02023-11-23T22:27:15ZengMDPI AGVaccines2076-393X2022-02-0110232410.3390/vaccines10020324Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected ParticipantsDavid Peterhoff0Sebastian Einhauser1Stephanie Beileke2Hans-Helmut Niller3Felix Günther4Michael Schachtner5Benedikt Asbach6Philipp Steininger7Matthias Tenbusch8Antonia S. Peter9Andre Gessner10Ralph Burkhardt11Iris M. Heid12Ralf Wagner13Klaus Überla14Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, GermanyInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyDepartment of Mathematics, Stockholm University, Kräftriket 6, 106 91 Stockholm, SwedenInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, GermanyInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, GermanyInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, GermanyInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyDepartment of Genetic Epidemiology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, GermanyInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, GermanyTo assess vaccine immunogenicity in non-infected and previously infected individuals in a real-world scenario, SARS-CoV-2 antibody responses were determined during follow-up 2 (April 2021) of the population-based Tirschenreuth COVID-19 cohort study comprising 3378 inhabitants of the Tirschenreuth county aged 14 years or older. Seronegative participants vaccinated once with Vaxzevria, Comirnaty, or Spikevax had median neutralizing antibody titers ranging from ID50 = 25 to 75. Individuals with two immunizations with Comirnaty or Spikevax had higher median ID50s (of 253 and 554, respectively). Regression analysis indicated that both increased age and increased time since vaccination independently decreased RBD binding and neutralizing antibody levels. Unvaccinated participants with detectable N-antibodies at baseline (June 2020) revealed a median ID50 of 72 at the April 2021 follow-up. Previously infected participants that received one dose of Vaxzevria or Comirnaty had median ID50 to 929 and 2502, respectively. Individuals with a second dose of Comirnaty given in a three-week interval after the first dose did not have higher median antibody levels than individuals with one dose. Prior infection also primed for high systemic IgA levels in response to one dose of Comirnaty that exceeded IgA levels observed after two doses of Comirnaty in previously uninfected participants. Neutralizing antibody levels targeting the spike protein of Beta and Delta variants were diminished compared to the wild type in vaccinated and infected participants.https://www.mdpi.com/2076-393X/10/2/324SARS-CoV-2vaccinationpopulation-based cohortimmunogenicityneutralizing antibodiesComirnaty |
| spellingShingle | David Peterhoff Sebastian Einhauser Stephanie Beileke Hans-Helmut Niller Felix Günther Michael Schachtner Benedikt Asbach Philipp Steininger Matthias Tenbusch Antonia S. Peter Andre Gessner Ralph Burkhardt Iris M. Heid Ralf Wagner Klaus Überla Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants Vaccines SARS-CoV-2 vaccination population-based cohort immunogenicity neutralizing antibodies Comirnaty |
| title | Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants |
| title_full | Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants |
| title_fullStr | Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants |
| title_full_unstemmed | Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants |
| title_short | Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants |
| title_sort | comparative immunogenicity of covid 19 vaccines in a population based cohort study with sars cov 2 infected and uninfected participants |
| topic | SARS-CoV-2 vaccination population-based cohort immunogenicity neutralizing antibodies Comirnaty |
| url | https://www.mdpi.com/2076-393X/10/2/324 |
| work_keys_str_mv | AT davidpeterhoff comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT sebastianeinhauser comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT stephaniebeileke comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT hanshelmutniller comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT felixgunther comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT michaelschachtner comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT benediktasbach comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT philippsteininger comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT matthiastenbusch comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT antoniaspeter comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT andregessner comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT ralphburkhardt comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT irismheid comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT ralfwagner comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants AT klausuberla comparativeimmunogenicityofcovid19vaccinesinapopulationbasedcohortstudywithsarscov2infectedanduninfectedparticipants |